2022 Q2 Form 10-Q Financial Statement

#000095017022014815 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q4
Revenue $3.693M $2.571M $367.0K
YoY Change 139.03% 182.53%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.576M $6.452M $9.717M
YoY Change 15.56% 11.63% 56.47%
% of Gross Profit
Research & Development $16.51M $31.68M $28.60M
YoY Change -32.76% 38.51% 1.84%
% of Gross Profit
Depreciation & Amortization $600.0K $676.0K $728.0K
YoY Change -25.0% -8.77% -0.27%
% of Gross Profit
Operating Expenses $24.09M $38.13M $38.32M
YoY Change -22.58% 33.08% 11.74%
Operating Profit -$20.39M -$35.56M
YoY Change -31.02% 28.18%
Interest Expense $212.0K $86.00K $44.00K
YoY Change 190.41% -21.82% -83.7%
% of Operating Profit
Other Income/Expense, Net $304.0K -$91.00K $132.0K
YoY Change -202.01% -1010.0% -169.47%
Pretax Income -$19.88M -$35.56M -$37.77M
YoY Change -33.28% 28.71% 10.44%
Income Tax $47.00K $53.00K -$58.00K
% Of Pretax Income
Net Earnings -$19.92M -$35.62M -$37.71M
YoY Change -33.18% 28.69% 9.57%
Net Earnings / Revenue -539.51% -1385.26% -10276.29%
Basic Earnings Per Share -$0.47 -$0.84
Diluted Earnings Per Share -$467.0K -$837.8K -$898.6K
COMMON SHARES
Basic Shares Outstanding 42.67M 42.51M
Diluted Shares Outstanding 42.67M 42.51M

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $159.3M $183.2M $190.7M
YoY Change -16.42% -14.14% -21.67%
Cash & Equivalents $71.17M $104.6M $186.8M
Short-Term Investments $88.17M $78.66M $3.918M
Other Short-Term Assets $8.320M $10.30M $13.53M
YoY Change 43.55% 60.86% 127.56%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $167.7M $195.1M $204.4M
YoY Change -14.73% -11.25% -18.24%
LONG-TERM ASSETS
Property, Plant & Equipment $5.781M $6.018M $6.180M
YoY Change -16.88% -58.5% -22.82%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $15.11M
YoY Change
Other Assets $616.0K $616.0K $866.0K
YoY Change -58.41% 208.0% 129.71%
Total Long-Term Assets $14.84M $15.39M $30.95M
YoY Change -2.6% 4.72% 102.45%
TOTAL ASSETS
Total Short-Term Assets $167.7M $195.1M $204.4M
Total Long-Term Assets $14.84M $15.39M $30.95M
Total Assets $182.5M $210.5M $235.4M
YoY Change -13.85% -10.25% -11.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.762M $3.755M $3.015M
YoY Change 73.38% 34.11% -8.99%
Accrued Expenses $12.82M $19.24M $25.39M
YoY Change -32.72% 43.57% 53.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $138.0K $138.0K $138.0K
YoY Change 430.77% 38.0%
Total Short-Term Liabilities $31.65M $41.36M $38.96M
YoY Change 5.17% 64.11% 28.68%
LONG-TERM LIABILITIES
Long-Term Debt $334.0K $365.0K $394.0K
YoY Change -15.87% 265.0% -21.2%
Other Long-Term Liabilities $133.0K $134.0K $133.0K
YoY Change -50.19% -99.04% -64.91%
Total Long-Term Liabilities $133.0K $134.0K $133.0K
YoY Change -50.19% -99.05% -64.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.65M $41.36M $38.96M
Total Long-Term Liabilities $133.0K $134.0K $133.0K
Total Liabilities $45.54M $57.58M $50.64M
YoY Change 5.93% 46.52% 11.88%
SHAREHOLDERS EQUITY
Retained Earnings -$358.6M -$338.7M -$303.1M
YoY Change 54.44% 73.5%
Common Stock $495.5M $491.4M $487.4M
YoY Change 23.46% 23.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $137.0M $152.9M $184.7M
YoY Change
Total Liabilities & Shareholders Equity $182.5M $210.5M $235.4M
YoY Change -13.85% -10.25% -11.28%

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q4
OPERATING ACTIVITIES
Net Income -$19.92M -$35.62M -$37.71M
YoY Change -33.18% 28.69% 9.57%
Depreciation, Depletion And Amortization $600.0K $676.0K $728.0K
YoY Change -25.0% -8.77% -0.27%
Cash From Operating Activities -$25.04M -$20.43M -$37.48M
YoY Change 8.78% -31.42% 90.45%
INVESTING ACTIVITIES
Capital Expenditures -$334.0K $515.0K -$336.0K
YoY Change 124.16% 67.75% 460.0%
Acquisitions
YoY Change
Other Investing Activities -$9.642M -$59.89M -$16.14M
YoY Change -196.42% -698.89% -207.62%
Cash From Investing Activities -$9.976M -$60.40M -$16.48M
YoY Change -201.27% -723.17% -210.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 83.00K -21.00K 552.0K
YoY Change -10.75% -126.92% -99.71%
NET CHANGE
Cash From Operating Activities -25.04M -20.43M -37.48M
Cash From Investing Activities -9.976M -60.40M -16.48M
Cash From Financing Activities 83.00K -21.00K 552.0K
Net Change In Cash -34.93M -80.86M -53.41M
YoY Change 167.24% 303.79% -128.32%
FREE CASH FLOW
Cash From Operating Activities -$25.04M -$20.43M -$37.48M
Capital Expenditures -$334.0K $515.0K -$336.0K
Free Cash Flow -$24.70M -$20.95M -$37.14M
YoY Change 8.03% -30.41% 89.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-63000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
164000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001799448
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39617
dei Entity Registrant Name
EntityRegistrantName
Aligos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4724808
dei Entity Address Address Line1
EntityAddressAddressLine1
One Corporate Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
466-6059
dei Security12b Title
Security12bTitle
Common Stock, par value, $0.0001 per share
CY2021Q4 us-gaap Liabilities
Liabilities
50638000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
309000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42690229
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5965000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
495538000
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
88172000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
3918000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
487347000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-358611000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-303072000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
50000
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
452000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
136981000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
8320000
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
184731000
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
182523000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
235369000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
13526000
algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
126000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
167685000
CY2022Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
3693000
CY2021Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
1545000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
6264000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
204424000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
320000000
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
2455000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8441000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8789000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
320000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
849000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16510000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-63000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5781000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6180000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38957000
CY2022Q2 us-gaap Long Term Investments
LongTermInvestments
0
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
15110000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
616000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
866000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
15000
CY2022Q2 us-gaap Assets
Assets
182523000
CY2021Q4 us-gaap Assets
Assets
235369000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2762000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10302000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
11287000
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
201000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
459000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-61000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
626000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42808288
dei Trading Symbol
TradingSymbol
ALGS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
287000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71172000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
186816000
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
21000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42808288
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42690229
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3015000
us-gaap Depreciation
Depreciation
1246000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12824000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25394000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2796000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2769000
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
138000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
138000
CY2022Q2 algs Deferred Revenue From Collaboration Current
DeferredRevenueFromCollaborationCurrent
13133000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
28000
CY2021Q4 algs Deferred Revenue From Collaboration Current
DeferredRevenueFromCollaborationCurrent
7641000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
31653000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
99000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
261000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
133000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
74000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
133000
CY2022Q2 algs Deferred Revenue From Collaboration Non Current
DeferredRevenueFromCollaborationNonCurrent
3253000
CY2022Q2 us-gaap Liabilities
Liabilities
45542000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24554000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
48186000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47422000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7576000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6556000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14028000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12337000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
24086000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
31110000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-154000
us-gaap Operating Expenses
OperatingExpenses
62214000
us-gaap Operating Expenses
OperatingExpenses
59759000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20078000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19924000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-20393000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29565000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
136981000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-29842000
us-gaap Operating Income Loss
OperatingIncomeLoss
-55950000
us-gaap Operating Income Loss
OperatingIncomeLoss
-57304000
CY2022Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
516000
CY2021Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-225000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
152886000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55941000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
510000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-114000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19877000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29790000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-55440000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57418000
CY2021Q2 us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
2000
us-gaap Other Comprehensive Income Defined Benefit Plans Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent
3000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
111000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
3554000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-154000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
447000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-24000
CY2022Q2 algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
60000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-402000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19924000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29818000
us-gaap Net Income Loss
NetIncomeLoss
-55539000
us-gaap Net Income Loss
NetIncomeLoss
-57492000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-154000
CY2021Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-26000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-402000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-66000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-57555000
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.53
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42665598
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37619039
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42590479
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37526650
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
184731000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
111000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
7034000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
891000
algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
144000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-402000
us-gaap Net Income Loss
NetIncomeLoss
-55539000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
136981000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
195220000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
213000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3209000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29818000
CY2021Q2 algs Vesting Of Early Excercised Common Stock Options Value
VestingOfEarlyExcercisedCommonStockOptionsValue
84000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-24000
us-gaap Depreciation
Depreciation
1511000
us-gaap Net Income Loss
NetIncomeLoss
-57492000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
168884000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
220943000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71193000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
168884000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
220039000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
187843000
us-gaap Net Income Loss
NetIncomeLoss
-55539000
us-gaap Net Income Loss
NetIncomeLoss
-57492000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71172000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
187650000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-70380000
us-gaap Share Based Compensation
ShareBasedCompensation
7786000
us-gaap Share Based Compensation
ShareBasedCompensation
6205000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-5595000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
221000
algs Increase Decrease In Right Of Use Assets
IncreaseDecreaseInRightOfUseAssets
278000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-253000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1834000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-12425000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1862000
algs Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-957000
algs Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-626000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-112000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
8745000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2455000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45469000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52814000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
5245000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
74776000
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
10000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
19541000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
111000
algs Payments On Deferred Offering Costs
PaymentsOnDeferredOfferingCosts
99000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
60000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
37000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
11000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
309000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
62000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
173000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-115787000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-33100000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
186980000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
21000
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
193000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71193000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
187843000
algs Market To Market Adjustments For Available For Sale Investments
MarketToMarketAdjustmentsForAvailableForSaleInvestments
-402000
algs Market To Market Adjustments For Available For Sale Investments
MarketToMarketAdjustmentsForAvailableForSaleInvestments
-66000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
184000
algs Vesting Of Early Exercised Options Value
VestingOfEarlyExercisedOptionsValue
144000
algs Vesting Of Early Exercised Options Value
VestingOfEarlyExercisedOptionsValue
126000
algs Change In Pension Obligation
ChangeInPensionObligation
3000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-358600000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-303100000
CY2022Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
159300000
algs Deferred Offering Costs In Accounts Payable And Accrued Liabilities
DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
637000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0.0%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.537%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Organization </span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Description of business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Aligos Therapeutics, Inc. (Aligos-US) was incorporated in the state of Delaware on February 5, 2018 (inception). On September 10, 2018, the Company formed Aligos Belgium BVBA (Aligos-Belgium), a limited liability company organized under the laws of Belgium. On March 30, 2020, the Company formed as a wholly owned subsidiary, Aligos Australia Pty LTD (Aligos-Australia), a proprietary limited company. On May 18, 2021, the Company formed as a wholly owned subsidiary, Aligos Therapeutics (Shanghai) Co. Ltd. (Aligos-Shanghai) and together with Aligos-US, Aligos-Belgium, and Aligos-Australia being the “Company” or “Aligos”.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Aligos is a clinical-stage biopharmaceutical company developing novel therapeutics to address unmet medical needs in viral and liver diseases, including for chronic hepatitis B, coronaviruses and non-alcoholic steatohepatitis (NASH).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is devoting substantially all of its efforts to the research and development of its drug candidates. The Company has not generated any product revenue to date. The Company is also subject to a number of risks similar to other companies in the biotechnology industry, including the uncertainty of success of its nonclinical studies and clinical trials, regulatory approval of drug candidates, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third-parties, product liability, and dependence on key individuals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initial public offering</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On October 20, 2020, the Company closed its initial public offering (IPO) at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share for net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">135.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million, after deducting underwriting discounts and commissions. On November 5, 2020, the underwriters of the IPO partially exercised their overallotment, resulting in an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">16.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and commissions.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company has incurred losses and negative cash flows from operations since its inception. As of June 30, 2022 and December 31, 2021, the Company had an accumulated deficit of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">358.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">303.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">, respectively. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of expanded research and development activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2022, the Company has unrestricted cash, cash equivalents and investments of approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">159.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> which is available to fund future operations. The Company expects to continue to spend substantial amounts to continue the nonclinical and clinical development of its current and future programs. If the Company is able to gain marketing approval for drug candidates that are being developed, it will require significant additional amounts of cash in order to launch and commercialize such drug candidates. In addition, other unanticipated costs may arise. Because the design and outcome of the Company’s planned and anticipated clinical trials is highly uncertain, the Company cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any drug candidate the Company may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company expects to finance its cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. In addition, the Company may seek additional capital to take advantage of favorable market conditions or strategic opportunities even if the Company believes it has sufficient funds for its current or future operating plans. Based on the Company’s research and development plans, the Company expects its existing unrestricted cash, cash equivalents and investments, will enable it to fund its operations for at least 12 months following the date the condensed consolidated financial statements are issued. However, the Company’s operating plan may change as a result of many factors currently unknown, and the Company may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty the Company’s future expenses given the dynamic nature of its business, the COVID-19 pandemic and the macro-economic environment generally.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company’s ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond its control. For example, the COVID-19 pandemic, the current inflationary economic environment and rising interest rates have resulted in a disruption of global financial markets. If the disruption persists or deepens, the Company could be unable to access additional capital, which could negatively affect its ability to consummate certain corporate development transactions or other important, beneficial or opportunistic investments. If additional funds are not available to the Company when needed, on terms that are acceptable to the Company, or at all, the Company may be required to: delay, limit, reduce or terminate nonclinical studies, clinical trials or other research and development activities or eliminate one or more of its development programs altogether; or delay, limit, reduce or terminate its efforts to establish manufacturing and sales and marketing capabilities or other activities that may be necessary to commercialize any future approved products, or reduce the Company’s flexibility in developing or maintaining its sales and marketing strategy.</span></p>
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
14288000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
13442000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8507000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7262000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5781000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6180000
CY2022Q2 us-gaap Depreciation
Depreciation
600000
us-gaap Depreciation
Depreciation
1200000
CY2021Q2 us-gaap Depreciation
Depreciation
800000
us-gaap Depreciation
Depreciation
1500000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
19068000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
40000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
19028000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
88613000
CY2022Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
88172000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88613000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88172000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3200000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6329000
CY2022Q2 algs Accrued Payables Current
AccruedPayablesCurrent
8637000
CY2021Q4 algs Accrued Payables Current
AccruedPayablesCurrent
17554000
CY2022Q2 algs Liability For Early Exercised Stocks Options Current
LiabilityForEarlyExercisedStocksOptionsCurrent
131000
CY2021Q4 algs Liability For Early Exercised Stocks Options Current
LiabilityForEarlyExercisedStocksOptionsCurrent
276000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
856000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1235000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12824000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25394000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
65688
CY2021 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
163855
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6204000
CY2021Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
us-gaap Net Income Loss
NetIncomeLoss
-57492000
CY2022Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42665598
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37619039
CY2022Q2 algs Aggregate Price For Share Repurchase
AggregatePriceForShareRepurchase
100000
CY2021Q4 algs Aggregate Price For Share Repurchase
AggregatePriceForShareRepurchase
300000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3994000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3448000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7780000
CY2022Q2 algs Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
0
algs Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
0
CY2021Q2 algs Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
0
algs Expense Related To Milestone Payments
ExpenseRelatedToMilestonePayments
0
CY2022Q2 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-19924000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-29818000
us-gaap Net Income Loss
NetIncomeLoss
-55539000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42590479
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37526650
CY2022Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.79
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.53
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9016086
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5775012
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9016086
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5775012

Files In Submission

Name View Source Status
0000950170-22-014815-index-headers.html Edgar Link pending
0000950170-22-014815-index.html Edgar Link pending
0000950170-22-014815.txt Edgar Link pending
0000950170-22-014815-xbrl.zip Edgar Link pending
algs-20220630.htm Edgar Link pending
algs-20220630.xsd Edgar Link pending
algs-20220630_cal.xml Edgar Link unprocessable
algs-20220630_def.xml Edgar Link unprocessable
algs-20220630_htm.xml Edgar Link completed
algs-20220630_lab.xml Edgar Link unprocessable
algs-20220630_pre.xml Edgar Link unprocessable
algs-ex31_1.htm Edgar Link pending
algs-ex31_2.htm Edgar Link pending
algs-ex32_1.htm Edgar Link pending
algs-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending